Summary: The new management team will bolster Experimentica's leadership, driving innovation and growth in preclinical ocular models.
Kuopio, Finland, April 13, 2023 – Experimentica Ltd. (“Experimentica” or the “Company”), a leading contract research organization (CRO) in preclinical ophthalmic drug discovery services, today announced the appointment of three new executives to its management team. Guillaume Demarne, PharmD, will join as Chief Business Officer, Marc Cerrada-Gimenez, PhD, as Chief Technology Officer, and Jeff Jamison, PhD, as Chief Development Officer. These strategic additions reflect the company’s ongoing commitment to fostering innovation, driving growth, and providing best-in-class services to its clients.
“We are delighted to recognize the outstanding contributions of Guillaume, Marc, and Jeff by bringing them to key positions within our management team,” said Giedrius Kalesnykas, PhD, President and Chief Executive Officer of Experimentica. “Their collective expertise and dedication have been instrumental in our success, and we are confident that their leadership will continue to propel Experimentica forward in the preclinical ocular research space.”
Guillaume Demarne, PharmD, brings over fifteen years of experience in the pharmaceutical industry, having held various leadership roles in business development, fundraising, and strategy. In his new role as Chief Business Officer, Guillaume will lead Experimentica’s global business development efforts, focusing on expanding the company’s client base and strategic partnerships.
Marc Cerrada-Gimenez, PhD, is an accomplished scientist with a strong background in Biotechnology and data-driven research. As Chief Technology Officer, Marc will spearhead the development and implementation of innovative technologies to optimize Experimentica’s preclinical research capabilities, ensuring the company remains at the forefront of scientific advancements in ocular disease modeling.
Jeff Jamison, PhD, has an extensive track record in preclinical contract research and animal model development, with a particular focus on Ophthalmology. In his position as Chief Development Officer, Jeff will oversee the expansion of Experimentica’s preclinical service offerings, guiding the development of novel ocular models to help Experimentica’s clients address unmet medical needs.
The addition of these seasoned professionals to the management team underlines Experimentica Ltd.’s commitment to delivering exceptional preclinical research services, while continuing to innovate and grow in the fast-paced ocular research sector.
Contact for media enquiries
Guillaume Demarne, PharmD, Chief Business Officer
Phone: +33 (0) 7 83 55 69 52